Martin Patricia A.
Transaction: 07/10/2026
BUY
Change
+766
Price
Not reported
Filing
07/10/2026
Type
BUY
AN2 Therapeutics, Inc.
ANTX • Biotechnology
$3.56
▲ +0.19 (+5.64%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$159.35M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 6.87Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 12:16 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.56
Change5.64%
Shares Out44.76M
Market Cap$159.35M
Enterprise Value$80.96M
52W Range1.00 - 7.19
Beta-0.99
P/E-4.39
P/B2.10
P/FCF-5.19
EV/EBITDA-2.11
EV/FCF-2.64
Price$3.56
Change5.64%
Shares Out44.76M
Market Cap$159.35M
Enterprise Value$80.96M
52W Range1.00 - 7.19
Beta-0.99
P/E-4.39
P/B2.10
P/FCF-5.19
EV/EBITDA-2.11
EV/FCF-2.64
Earnings Yield-22.77%
FCF Yield-19.25%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio6.87
Quick Ratio6.87
Target$9.00
Target Upside152.81%
Target Median$9.00
Target Range9.00 - 9.00
Volume429.19K
Avg Volume298.20K
EPS Surprise-0.06
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 6.87Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-10-20
81/100
Bullish
Bullish
5
Hold
3
Bearish
0
Price Target
2026-08-13
Low
$9.00
Mean
$9.00
Median
$9.00
High
$9.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Marks Gilbert Lynn
Transaction: 07/10/2026
BUY
Change
+2,789
Price
Not reported
Filing
07/10/2026
Type
BUY
Aziz Kabeer
Transaction: 07/10/2026
BUY
Change
+2,852
Price
Not reported
Filing
07/10/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Martin Patricia A. | BUY | +766 | Not reported | 07/10/2026 | 07/10/2026 |
| Marks Gilbert Lynn | BUY | +2,789 | Not reported | 07/10/2026 | 07/10/2026 |
| Aziz Kabeer | BUY | +2,852 | Not reported | 07/10/2026 | 07/10/2026 |
| Eizen Joshua M | SELL | -5,945 | $4.17 | 07/08/2026 | 07/10/2026 |
| Williams Sarah Joanne | SELL | -265 | $4.43 | 05/29/2026 | 06/02/2026 |
| Martin Patricia A. | BUY | +1,192 | Not reported | 04/10/2026 | 04/10/2026 |
| Marks Gilbert Lynn | BUY | +3,775 | Not reported | 04/10/2026 | 04/10/2026 |
| Aziz Kabeer | BUY | +3,775 | Not reported | 04/10/2026 | 04/10/2026 |
| Easom Eric | SELL | -267,650 | $11.99 | 03/19/2026 | 03/23/2026 |
| Readnour Robin Shane | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| Spigelman Melvin K | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| Eizen Joshua M | SELL | -50,150 | $14.29 | 03/19/2026 | 03/23/2026 |
| Zakrzewski Joseph S | SELL | -10,362 | $17.28 | 03/19/2026 | 03/23/2026 |
| Wong Stephanie | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| FitzPatrick Margaret M | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| Martin Patricia A. | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| Aziz Kabeer | SELL | -23,742 | $5.91 | 03/19/2026 | 03/23/2026 |
| Marks Gilbert Lynn | SELL | -10,665 | $6.60 | 03/19/2026 | 03/23/2026 |
| Chanda Sanjay | SELL | -57,950 | $14.29 | 03/19/2026 | 03/23/2026 |
| Day Lucy | SELL | -82,300 | $14.29 | 03/19/2026 | 03/23/2026 |